Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Nancy E Davidson

Showing results (51-60 of 285) with videos related to

Pageof 29
Sort By:
Oncology (Williston Park, N.Y.)|October 9, 2004
Trastuzumab in breast cancerLeisha A Emens, Nancy E Davidson
The New England Journal of Medicine|January 20, 2006
Estrogen carcinogenesis in breast cancerJames D Yager, Nancy E Davidson
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 1, 2006
Still waiting after 110 years: the optimal use of ovarian ablation as adjuvant therapy for breast cancerAntonio C Wolff, Nancy E Davidson
Journal of the National Cancer Institute|September 20, 2017
Searching for the IDEAL Duration of Adjuvant Endocrine TherapyRachel L Yung, Nancy E Davidson
Journal of the National Cancer Institute|July 22, 2023
Are we there yet? Optimal duration of endocrine therapy in women with postmenopausal early-stage hormone receptor-positive breast cancerLynn K Symonds, Nancy E Davidson
Nature Reviews. Clinical Oncology|August 9, 2017
Breast cancer: What lies beyond APHINITY for HER2-positive breast cancer?Sasha E Stanton, Nancy E Davidson
Cancer Biology & Therapy|May 22, 2004
Estrogen receptor status, cell cycling and paclitaxel: looking for a "hormone"-ious explanationBen Ho Park, Nancy E Davidson
Oncology (Williston Park, N.Y.)|March 15, 2014
Adjuvant endocrine therapy for breast cancer: how long is long enough?Rachel C Jankowitz, Nancy E Davidson
Cancer|January 28, 2003
The biology of breast carcinomaJudith Clancy Keen, Nancy E Davidson
Nature Reviews. Clinical Oncology|January 15, 2014
Breast cancer in 2013: Genomics, drug approval, and optimal treatment durationAdrian V Lee, Nancy E Davidson
Pageof 29

Showing results (51-60 of 285) with videos related to

Sort By:
Pageof 29
Oncology (Williston Park, N.Y.)|October 9, 2004
Trastuzumab in breast cancerLeisha A Emens, Nancy E Davidson
The New England Journal of Medicine|January 20, 2006
Estrogen carcinogenesis in breast cancerJames D Yager, Nancy E Davidson
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 1, 2006
Still waiting after 110 years: the optimal use of ovarian ablation as adjuvant therapy for breast cancerAntonio C Wolff, Nancy E Davidson
Journal of the National Cancer Institute|September 20, 2017
Searching for the IDEAL Duration of Adjuvant Endocrine TherapyRachel L Yung, Nancy E Davidson
Journal of the National Cancer Institute|July 22, 2023
Are we there yet? Optimal duration of endocrine therapy in women with postmenopausal early-stage hormone receptor-positive breast cancerLynn K Symonds, Nancy E Davidson
Nature Reviews. Clinical Oncology|August 9, 2017
Breast cancer: What lies beyond APHINITY for HER2-positive breast cancer?Sasha E Stanton, Nancy E Davidson
Cancer Biology & Therapy|May 22, 2004
Estrogen receptor status, cell cycling and paclitaxel: looking for a "hormone"-ious explanationBen Ho Park, Nancy E Davidson
Oncology (Williston Park, N.Y.)|March 15, 2014
Adjuvant endocrine therapy for breast cancer: how long is long enough?Rachel C Jankowitz, Nancy E Davidson
Cancer|January 28, 2003
The biology of breast carcinomaJudith Clancy Keen, Nancy E Davidson
Nature Reviews. Clinical Oncology|January 15, 2014
Breast cancer in 2013: Genomics, drug approval, and optimal treatment durationAdrian V Lee, Nancy E Davidson
Pageof 29